Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 5/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | RXRG | P48443 | 2/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703850 | 0.91 | FPR2 (0.42) | FPR2RXRARXRBRXRGNR4A2 | |
| SCHEMBL1704592 | 0.91 | FPR2 (0.37) | FPR2SLC9A1PTGER1PIN1PTPN11 | |
| SCHEMBL1703980 | 0.91 | PTGER1 (0.35) | IKBKBFPR2NR4A2PTGER1 | |
| SCHEMBL1704018 | 0.89 | IKBKB (0.43) | IKBKBFPR2RXRARXRBKMT2A | |
| SCHEMBL1704368 | 0.89 | LRRK2 (0.34) | FPR2PTGER1 | |
| SCHEMBL2329257 | 0.87 | IKBKB (0.43) | IKBKBFPR2MDM2RXRARXRB | |
| SCHEMBL1703858 | 0.86 | RAB9A (0.33) | IKBKBFPR2PTGER1 | |
| SCHEMBL1704456 | 0.84 | IKBKB (0.41) | IKBKBFPR2MDM2RXRARXRB | |
| SCHEMBL2330747 | 0.80 | IKBKB (0.44) | IKBKBMDM2RXRARXRBRXRG | |
| SCHEMBL2328798 | 0.79 | PTGER1 (0.38) | IKBKBFPR2SLC9A1PTGER1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | claimed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | claimed |
| US-8580831-B2 | Fluorinated aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | AFF1, SULT2A1, NAT1 | IKBKB 4277/4885FPR2 217/4885MDM2 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.